Use of Implantable Venous Port Systems in the Treatment of Children with Orphan Diseases (Mucopolysaccharidosis and Pompe Disease): Case Series

Many orphan diseases in children require life-long and regular intravenous enzyme replacement therapy. The article describes the first Russian practice of implanting venous port systems in 12 patients with type I and II mucopolysaccharidosis and Pompe disease (6 months to 17 years old) to create long-term venous access. Currently, implantable venous port systems are used in 9 (75%) of 12 patients. 4 cases of thrombosis are observed in 3 patients. All of them have been successfully treated. 1 patient had a rotation of the port camera with a membrane facing downwards due to violation of an implantation technique. The camera was adjusted during the second operation.

1. Scheinfeld N. S., Tabamo R. E., Klein B. Lysosomal storage disease. Medscape Reference. 2008. URL: http://emedicine. medscape.com/article/1182830-overview#section~WolmanDisea seandCholesterylEsterStorageDisease (available: 24.07.2015).

2. Hendriksz C. J. Mucopolysaccharidoses. J. Inherit. Metab. Dis. 2013; 36 (2): 177–178.

3. Hirschhorn R., Reuser A. J. J. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: The Metabolicand Molecular Bases of Inherited Disease. A. Beaudet, C. Scriver, W. Sly et al. (eds.). New York: McGraw Hill. 2001. P. 3389–3420.

4. Рыков М. Ю., Гьокова Е. В., Поляков В. Г. Этюды катетеризации центральных вен. Избранные моменты техники. Онкопедиатрия. 2014; 1 (3): 5–13.

5. Рыков М. Ю., Кириллова О. А., Поляков В. Г. Роль лучевых методов диагностики в обеспечении венозного доступа. Онкопедиатрия. 2015; 2 (1): 7–15.

6. Valayannopoulos V., Wijburg F. A. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011; 50 (Suppl. 5): 49–59.

7. Nicolino M., Byrne B., Wraith J. E., Leslie N., Mandel H., Freyer D. R. Clinical outcomes after long-term treatment with alglucosidasealfa in infants and children with advanced Pompe disease. Genet. Med. 2009; 11: 3: 210–209.

8. Angelini C., Semplicini C. Enzyme Replacement Therapy for Pompe Disease. Curr. Neurol. Neurosci. Rep. 2012; 12: 70–75.

9. Басаргина Е. Н., Жарова О. П., Архипова Е. Н., Сугак А. Б., Талалаев А. Г., Журкова Н. В. Опыт применения ферментозаместительной терапии рекомбинантной человеческой кислой альфа-глюкозидазой у детей с инфантильной формой болезни Помпе. Российский вестник перинатологии и педиатрии. 2013; 6: 58–66.

10. Orchard P. J., Milla C., Braunlin E., Defor T., Bjoraker K., Blazar B. R., Peters C., Wagner J., Tolar J. Pre-transplant risk factors affecting outcome in Hurler syndrome. Bone Marrow Transplant. 2010; 45: 1239–1246.

11. Frawley G., Fuenzalida D., Donath S., Yapito-Lee J., Peters H. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses. Pediatr. Anaesth. 2012; 22 (8): 737–744.

12. Walker R., Belani K. G., Braunlin E. A., Bruce I. A., Hack H., Harmatz P. R., Jones S., Rowe R., Solanki G. A., Valdemarsson B. Anaesthesia and airway management in mucopolysaccharidosis. J. Inherit. Metab. Dis. 2013; 36: 211–219.

13. White Klane K. Orthopaedic aspects of mucopolysacchari doses. Rheumatology. 2011; 50 (26): 33.

14. Belani K. G., Krivit W., Carpenter B. L. M., Braunlin E., Buckley J. J., Liao J. C., Floyd T., Leonard A. S., Summers C. G. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J. Pediatr. Surg. 1993; 28: 403–408.

15. Moores C., Rogers J. G., McKenzie I. M., Brown T. C. K. Anaesthesia for children with mucopolysaccharidoses. Anaesth. Intensive Care. 1996; 24: 459–463.

16. Thorne J. A., Javadpour M., Hughes D. G., Wraith E., Cowie R. A. Craniovertebral abnormalities in Type VI mucopolysaccharidosis (Maroteaux–Lamy syndrome). Neurosurgery. 2001; 48: 849–852.

17. Sims H. S., Kempiners J. J. Special airway concerns in patients with mucopolysaccharidoses. Respir. Med. 2007; 101: 1779–1782.

18. McLaughlin A. M., Farooq M., Donnelly M. B., Foley K. Anaesthetic considerations of adults with Morquio’s syndrome — a case report. BMC Anesthesiol. 2010; 10: 2.

19. Valayannopoulos V., Nicely H., Harmatz P., Turbeville S. Mucopoly saccharidosis VI. Orphanet J. Rare Dis. 2010; 5: 5.

20. Walker R. W. M., Darowski M., Morris P., Wraith J. E. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia. 1994; 49: 1078–1084.

21. Leal G. N., de Paula A. C., Leone C., Kim C. A. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol. Young. 2010; 20: 254–261.

22. Burton B., Guffon N., Roberts J., van der Ploeg A., Jones S. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccaridosis type II — data from the Hunter outcome Survey. Mol. Genet. Metabol. 2010; 101 (2–3) 123–129.

23. Расулов Р. И., Зубков Р. А., Дворниченко В. В., Сонголов Г. И., Загайнов А. С. Полностью имплантируемые системы для венозного доступа: анализ осложнений. Сибирский медицинский журнал. 2013; 3: 105–108.

24. Бучинская Н. В., Чикова И. А., Исупова Е. А., Калашникова О. В., Костик М. М., Часнык В. Г. Современные подходы к терапии мукополисахаридозов у детей. Вопросы современной педиатрии. 2014; 13 (3): 35–43.

25. Muenzer J., Hendriksz C., Fan Z., Vijayaraghavan S., Perry V., Santra S., Solanki G. A., Mascelli M. A., Pan L., Wang N., Sciarappa K., Barbier A. J. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccaridosis II. Genet. Med. 2015; doi: 10.1038/gim.2015.36

26. Sakakibara M., Teramoto Y., Aoyama T., Hara M., Maseki M., Yamaguchi S., Nakata J. A case report of anesthesia for a child with Pompe’s disease (glycogen storage disease type II). Masui. 2009; 58 (2): 219–222.

27. Giugliani R., Harmatz P., Wraith J. Management Guidelines for Mucopolysaccaridosis VI. Pediatrics. 2007; 120 (2): 405–418.

28. Blanchette V. S., al-Musa A., Stain A. M., Filler R. M., Ingram J. Central venous access catheters in children with haemophilia. Blood Coagul. Fibrinolysis. 1996; 7 (Suppl. 1): 39–44.

29. Vepsalainen K., Lassila R., Arola M., Lahteenmaki P., Mottonen M., Makipernaa A., Riikonen P. Complications associated with central venous access in children with haemophilia: a nationwide multicenter study in Finland. Haemophilia. 2015; doi: 10.1111/hae.12665.

30. Aldrighetti L., Paganelli M., Arru M., Caterini R., Ronzoni M., Ferla G. Complications of blind placement technique in 980 subcutaneous infusion ports. J. Vasc. Access. 2000; 1 (1): 28–32.

31. Skiest D. J., Grant P., Keiser P. Nontunneled central venous catheters in patients with AIDS are associated with a low infection rate. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998; 17 (3): 220–226.

32. Domingo P., Fontanet A., Sanchez F., Allende L., Vazquez G. Morbidity associated with long-term use of totally implantable ports in patients with AIDS. Clin. Infect. Dis. 1999; 29 (2): 346–351.